Sirtex Medical appoints Dr. Mark A. Turco as Global Chief Medical Officer and EVP of Research & Development

Wednesday 03 June 2020
WOBURN, Mass. (June 3, 2020) –– Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced the appointment of Dr. Mark A. Turco, FACC, as Global Chief Medical Officer and EVP of Research & Development, effective June 1, 2020.

Industry veteran to lead Medical and Clinical Affairs to advance clinical trials and accelerate further development of cancer therapies

With more than three decades of experience, Dr. Turco will serve as the company’s principal medical expert and corporate leader of Medical and Clinical Affairs. He will develop the strategic vision for Sirtex’s clinical trial portfolio, including registration and post-registration trials. Under his leadership, the Sirtex team will continue to support and promote the company’s products to further advance the field of oncology treatment and deliver the highest level of patient care and provider focus. Dr. Turco will also be responsible for ensuring the accuracy of medical input, building the company’s R&D function and developing key external relationships.

"Dr. Turco brings an extraordinary, diverse background as a board-certified interventional cardiologist, clinical researcher, healthcare and business executive, as well as expertise in academic innovation," said Kevin R. Smith, Chief Executive Officer of Sirtex. "We're thrilled to welcome him to the team and we look forward to working together to further our mission of patient-first oncology innovation."

Based out of Sirtex’s global headquarters in Woburn, Massachusetts, Dr. Turco will serve as a member of the Senior Leadership Team and report directly to Mr. Smith.

"It's an honor to join Sirtex at this important time of advancing our clinical trial portfolio and driving product growth," said Dr. Turco. "I'm excited to join this outstanding team as we deliver the best therapies to patients living with cancer and beyond."

Prior to joining Sirtex, Dr. Turco served as Chief Innovation and Corporate Outreach Officer for the University of Pennsylvania’s Penn Center for Innovation (PCI). In this role, he developed industry and academic partnerships as well as drove academic translation through technology incubation, acceleration and company creation. Before UPenn, Dr. Turco served as Vice President and Chief Medical Officer for the Aortic, Peripheral and Vascular Divisions at Medtronic, where he managed a large interdisciplinary team and oversaw business ventures, clinical trials, as well as publication strategies for key scientific data. Dr. Turco joined Medtronic in its acquisition of Covidien, where he served as Chief Medical Officer. Previously, Dr. Turco held the role of Director of the Center for Cardiac and Vascular Research at Washington Adventist Hospital in Takoma Park, Maryland, leading large-scale medical device and pharmaceutical trials.

About Sirtex

Sirtex is a global healthcare business with offices in the U.S., Australia, Europe and Asia, working to improve outcomes in people with cancer. Sirtex’s current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,300 medical centers in over 45 countries. For more information, visit www.sirtex.com. SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.


Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

This content is intended for journalists only

By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage

Effective May 7, 2021, SIR-Spheres will have the following indication for use:
SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

Click here to view our Technical Bulletin.

Ok